Incyte (WBO:INCY) Land And Improvements

: €10 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

Incyte's land and improvements for the quarter that ended in Dec. 2023 was €10 Mil.

Incyte's quarterly land and improvements increased from Jun. 2023 (€10 Mil) to Sep. 2023 (€10 Mil) and increased from Sep. 2023 (€10 Mil) to Dec. 2023 (€10 Mil).

Incyte's annual land and improvements increased from Dec. 2021 (€9 Mil) to Dec. 2022 (€10 Mil) and increased from Dec. 2022 (€10 Mil) to Dec. 2023 (€10 Mil).

Incyte Land And Improvements Historical Data

The historical data trend for Incyte's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

9.18

8.77

9.29

9.85

10.02

Incyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Land And Improvements																9.85	9.79	9.77	9.82	10.02

Incyte Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Incyte (WBO:INCY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (WBO:INCY) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.